IIIldikó Istenes

Ildikó Istenes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ildikó Istenes has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Felnőttkorban felismert hypocalcaemia és immunhiány ritka oka

    by Sára Zsigrai, János Kósa, Zsófia Szili-Janicsek, Ildikó Istenes, Péter Lakatos, Judit Demeter, Balázs Szili

    A közleményben egy 37 éves nőbeteg esetét ismertetjük. Gyermekkorában Fallot-tetralógia miatt rekonstrukciós műtétet végeztek. 29 éves korában visszatérő alsó légúti fertőzések miatt vizsgálták, közönséges változó immunhiány (alacsony immunglobulin szintekkel) derült ki. Klinikánkon immunglobulinpótlás indult, ekkor derült ki súlyos hypocalcaemiája. Ennek hátterében szabályos magnéziumszint mellett alacsony szérumparathormon-szint igazolódott, ami alapján a hypoparathyreosis diagnózisa volt felállítható. A beteg arcát érintő fenotípusos jellegzetességek (ellapult philtrum, széles orrnyereg), veleszületett szívfejlődési rendellenesség alapján DiGeorge-szindróma alapos gyanúja merült fel, amit a genetikai vizsgálat megerősített. Az immunhiány részletes vizsgálata közönséges variabilis immunhiányt igazolt, ami nem a szindróma része, valószínűleg véletlen társulás. Érdekes azonban, hogy a DiGeorge-szindrómára jellemző thymus-hiányhoz társuló T-sejt defektus nem volt megfigyelhető. A DiGeorge-szindróma több szervrendszert érintő örökletes megbetegedés, amely jellemzően kisgyermekkorban kerül felismerésre kongenitális szívbetegség vagy tüneteket okozó súlyos hypocalcaemia kapcsán. Az eset különlegességét az adja, hogy a hypocalcaemia csak felnőttkorban került felismerésre, és a társuló immunhiány nem a szindróma részjelensége.

  • Open Access

    Associations Between Previously Identified Genetic Variants and Clinical Phenotypes of Diabetic Neuropathy in Type 2 Diabetes: An Exploratory Analysis of the Discovery Cohort

    by Noémi Hajdú, Zsófia Ludvig, Ramóna Rácz, Ildikó Istenes, Magdolna Békeffy, Orsolya Erzsébet Vági, Anna Erzsébet Körei, Eszter Horváth, Bálint Tóbiás, Anett Illés, et al.

    Diabetic neuropathy is a common and multifactorial complication of type 2 diabetes, in which genetic susceptibility is increasingly recognized as a contributing factor. This study (cross-sectional case–control) aimed to investigate the associations between previously identified genetic variants and clinically relevant neurophysiological and symptomatic parameters. A total of 48 individuals with type 2 diabetes (24 with neuropathy and 24 without) were included. Neuropathy was assessed using standardized neurological, sensory, and cardiovascular autonomic function tests. Genetic variants were selected in a prior discovery analysis of this same cohort and re-tested here, precluding independent validation. Associations between genetic variants and clinical parameters were assessed through group-based comparisons using Mann–Whitney U tests and Fisher’s exact test, correlation analysis using Spearman’s rank correlation, permutation-based testing to improve robustness, and multivariable linear regression adjusted for age and sex to account for potential demographic confounding (q < 0.1). Mann–Whitney U test analysis identified several associations between genetic variants and neuropathy-related clinical parameters. In the Mann–Whitney U test analysis, only the rs6682221 variant remained significantly associated with heat detection threshold in the left hand after false discovery rate correction (p = 0.000150; q = 0.02736), although this association did not remain significant in the complementary permutation analysis based on median differences. Spearman’s rank correlation analysis identified a significant positive association between rs6682221 allele burden and heat detection threshold in the left hand, which remained significant after permutation correction (r = 0.552, p = 0.000086, q = 0.016). Multivariable regression adjusted for age and sex revealed several independent associations between selected variants and sensory neuropathy-related parameters. These findings should be considered exploratory, as all analyses were performed within the original discovery cohort and no independent validation cohort was available. Independent replication and functional studies are required before any clinical relevance can be inferred.

  • Open Access

    Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis

    by Hermina Sánta, Laura Regáli, László Váróczy, Virág Szita, Ádám Wiedemann, Lóránt Varju, László Rejtő, Norbert Sándor Bartha, Dorottya Máté, András Masszi, et al.

    Background/Objectives: Despite therapeutic advances, managing relapsed/refractory multiple myeloma (RRMM) remains challenging. For patients with frailty, comorbidities, mobility limitations, or when treatment preference and drug accessibility are key considerations, the all-oral ixazomib–lenalidomide–dexamethasone (IRd) regimen offers a practical alternative. Methods: We performed a multicenter retrospective study of RRMM patients treated with IRd in Hungary between 1 January 2020 and 30 June 2025. Results: The median age at treatment initiation was 73.7 years. Treatment was initiated for clinical progression in 38.2%, biochemical progression in 53.3%, and for intolerance or toxicity of prior therapy in 8.6%. Median progression-free survival (PFS) was 18.7 months, and median overall survival (OS) was 34.7 months. Patients treated at biochemical progression had significantly longer PFS than those treated at clinical progression (24.3 vs. 15.6 months; p = 0.004), with additional benefit when IRd was initiated owing to intolerance or toxicity of previous therapy (p = 0.04). In the second-line setting, median PFS was 24.5 months, and median OS was not reached. Adverse events occurred in 68.3% of patients; dose reductions were required in 18.4%, and 21.6% discontinued treatment because of intolerance or toxicity. Most common toxicities were neutropenia (32.9%), thrombocytopenia (27.6%), diarrhoea (25%), peripheral neuropathy (25.3%), and infections (22.4%). Conclusions: IRd initiation at biochemical progression was associated with superior PFS compared with treatment at clinical progression. When compared with a recent Hungarian multicenter cohort treated with second-line daratumumab, lenalidomide, and dexamethasone, outcomes with IRd are not significantly inferior (36-month OS calculated from 2nd line treatment initiation: 65.5% for DRd vs. 60% in our cohort; p = 0.56). These real-world data support IRd as an effective, convenient, all-oral option for appropriately selected RRMM patients.


  • Open Access

    Novel Genetic Variants Associated with Diabetic Neuropathy Risk in Type 2 Diabetes: A Whole-Exome Sequencing Approach

    by Noémi Hajdú, Dóra Zsuzsanna Tordai, Ramóna Rácz, Zsófia Ludvig, Ildikó Istenes, Magdolna Békeffy, Orsolya Erzsébet Vági, Anna Erzsébet Körei, Bálint Tóbiás, Anett Illés, et al.

    The pathogenesis of diabetic neuropathy involves complex interactions between metabolic and genetic factors. This study aimed to identify novel genetic variants associated with neuropathy risk in type 2 diabetes through reanalysis of whole-exome sequencing data. We identified seven new SNPs with significant associations, including intronic variants in TTN, PLCB1, CCNI, and CDC34 and a 5′-upstream variant in BTG2. These variants are implicated in muscle elasticity, neurotransmission, endothelial regeneration, and apoptosis resistance, suggesting multifaceted genetic contributions to neuropathy development. These findings enhance our understanding of diabetic neuropathy and may support future advances in risk stratification and therapy development.


  • Open Access

    Genetic Variants Influence the Development of Diabetic Neuropathy

    by Noémi Hajdú, Ramóna Rácz, Dóra Zsuzsanna Tordai, Magdolna Békeffy, Orsolya Erzsébet Vági, Ildikó Istenes, Anna Erzsébet Körei, Peter Kempler, Zsuzsanna Putz

    The exact mechanism by which diabetic neuropathy develops is still not fully known, despite our advances in medical knowledge. Progressing neuropathy may occur with a persistently favorable metabolic status in some patients with diabetes mellitus, while, in others, though seldom, a persistently unfavorable metabolic status is not associated with significant neuropathy. This might be significantly due to genetic differences. While recent years have brought compelling progress in the understanding of the pathogenetic background—in particular, accelerated progress is being made in understanding molecular biological mechanisms—some aspects are still not fully understood. A comparatively small amount of information is accessible on this matter; therefore, by summarizing the available data, in this review, we aim to provide a clearer picture of the current state of knowledge, identify gaps in the previous studies, and possibly suggest directions for future studies. This could help in developing more personalized approaches to the prevention and treatment of diabetic neuropathy, while also taking into account individual genetic profiles.


  • Open Access

    Genetic Factors Associated with the Development of Neuropathy in Type 2 Diabetes

    by Dóra Zsuszanna Tordai, Noémi Hajdú, Ramóna Rácz, Ildikó Istenes, Magdolna Békeffy, Orsolya Erzsébet Vági, Miklós Kempler, Anna Erzsébet Körei, Bálint Tóbiás, Anett Illés, et al.

    Neuropathy is a serious and frequent complication of type 2 diabetes (T2DM). This study was carried out to search for genetic factors associated with the development of diabetic neuropathy by whole exome sequencing. For this study, 24 patients with long-term type 2 diabetes with neuropathy and 24 without underwent detailed neurological assessment and whole exome sequencing. Cardiovascular autonomic function was evaluated by cardiovascular reflex tests. Heart rate variability was measured by the triangle index. Sensory nerve function was estimated by Neurometer and Medoc devices. Neuropathic symptoms were characterized by the neuropathy total symptom score (NTSS). Whole exome sequencing (WES) was performed on a Thermo Ion GeneStudio S5 system determining the coding sequences of approximately 32,000 genes comprising 50 million base pairs. Variants were detected by Ion Reporter software and annotated using ANNOVAR, integrating database information from dbSNP, ClinVar, gnomAD, and OMIM. Integrative genomics viewer (IGV) was used for visualization of the mapped reads. We have identified genetic variants that were significantly associated with increased (22–49-fold) risk of neuropathy (rs2032930 and rs2032931 of recQ-mediated genome instability protein 2 (RMI2) gene), rs604349 of myosin binding protein H like (MYBPHL) gene and with reduced (0.07–0.08-fold) risk (rs917778 of multivesicular body subunit 12B (MVB12B) and rs2234753 of retinoic acid X receptor alpha (RXRA) genes). The rs2032930 showed a significant correlation with current perception thresholds measured at 5 Hz and 250 Hz for n. medianus (p = 0.042 and p = 0.003, respectively) and at 5 Hz for n. peroneus (p = 0.037), as well as the deep breath test (p = 0.022) and the NTSS (p = 0.023). The rs2032931 was associated with current perception thresholds (p = 0.003 and p = 0.037, respectively), deep breath test (p = 0.022), and NTSS (p = 0.023). The rs604349 correlated with values measured at 2000 (p = 0.049), 250 (p = 0.018), and 5 Hz (p = 0.005) for n. medianus, as well as warm perception threshold measured by Medoc device (p = 0.042). The rs2234753 showed correlations with a current perception threshold measured at 2000 Hz for n. medianus (p = 0.020), deep breath test (p = 0.040), and NTSS (p = 0.003). There was a significant relationship between rs91778 and cold perception threshold (p = 0.013). In our study, genetic variants have been identified that may have an impact on the risk of neuropathy developing in type 2 diabetic patients. These results could open up new opportunities for early preventive measures and might provide targets for new drug developments in the future.


  • Open Access

    Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia

    by Zsófia F. Nagy, Kata Ferenczi, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Hairy cell leukaemia (HCL) is a rare B cell malignancy with an indolent course leading to pancytopaenia due to bone marrow infiltration. It has been proposed that HCL patients are at risk of developing a secondary malignancy, with a marked likelihood of the development of other hematologic malignancies including Hodgkin lymphoma and high-grade non-Hodgkin lymphomas. Here, we present the case of two patients who developed diffuse large B cell lymphoma after a long course of hairy cell leukaemia. In the case of the female patient, we report on the occurrence of a third malignant disease, which is very uncommon. With our case descriptions we contribute to the very small number of similar cases reported.


  • Open Access

    Association of Cardiovascular Autonomic Neuropathy and Distal Symmetric Polyneuropathy with All-Cause Mortality: A Retrospective Cohort Study

    by Orsolya E. Vági, Márk M. Svébis, Beatrix A. Domján, Anna E. Körei, Ildikó Istenes, Zsuzsanna Putz, Szilvia Mészáros, Noémi Hajdú, Magdolna Békeffy, Solomon Tesfaye, et al.

    Background. People with diabetic cardiovascular autonomic neuropathy (CAN) have increased cardiovascular mortality. However, the association between distal symmetric polyneuropathy (DSPN) or CAN with all-cause mortality is much less investigated. Thus, we set out to examine the effect of CAN and DSPN on all-cause mortality in a well-phenotyped cohort. Methods. All diabetes cases ( n = 1,347 ) from the catchment area of a secondary diabetes care centre who had medical examination including neuropathy assessment between 1997 and 2016 were followed up for all-cause mortality in the NHS Hungary reimbursement database until 2018. We investigated the association of CAN (Ewing tests) and DSPN (Neurometer) with all-cause mortality using Cox models stratified by diabetes type. Results. Altogether, n = 131 / 1,011 persons with type 1/type 2 diabetes were included. Of the participants, 53%/43% were male, mean age was 46 ± 12 / 64 ± 10 years, diabetes duration was 13 ± 10 / 7 ± 8 years, 42%/29% had CAN, and 39%/37% had DSPN. During the 9 ± 5 / 8 ± 5 -year follow-up, n = 28 / 494 participants died. In fully adjusted models, participants with type 1 diabetes patients with versus without DSPN had an increased mortality (HR 2.99, 95% CI 1.4-8.63), while no association with CAN was observed. In type 2 diabetes, both DSPN and CAN independently increased mortality (HR 1.32, 95% CI: 1.07-1.64, and HR 1.44, 95% CI: 1.17-1.76). Conclusions. Our results are compatible with an increased risk of mortality in people with type 1 diabetes and DSPN. Furthermore, we report a similarly strong association between DSPN and CAN and all-cause mortality in type 2 diabetes mellitus.


  • Open Access

    Súlyos atípusos amyotrophia (radiculoplexus neuropathia) újonnan felismert 2-es típusú diabetesben és COVID-19-infekcióban szenvedő betegben – esetismertetés

    by Anna Körei, Magdolna Békeffy, Ildikó Istenes, Edit Román, Zsuzsanna Putz, Dóra Tordai, Noémi Hajdú, Orsolya Vági, Péter Kempler

  • Új irányok a daganatellenes kezelés indukálta szenzoros neuropathiák kezelésében

    by Ildikó Istenes, Ágnes Vincze, Judit Demeter, Zsolt Nagy

    Absztrakt: Számos kemoterápiás készítmény dózislimitáló mellékhatása a kemoterápia indukálta perifériás neuropathia, azonban nemcsak a klasszikus kemoterápiás kezelés kapcsán léphet fel idegkárosodás, hanem az új típusú daganatellenes gyógyszerek (pl. proteaszómagátlók, immunmodulánsok, molekulárison célzott kezelések) esetében is számolni kell ezzel a szövődménnyel. Ez a mellékhatás a kezelés alatt és hosszú távon is kedvezőtlenül befolyásolja a beteg életminőségét és a gyógyszer dózisának csökkentésére, esetleg felfüggesztésére kényszerítheti a kezelőorvost, ami viszont a beteg gyógyulási esélyeit ronthatja. Mivel jelenleg nem áll rendelkezésre bizonyítottan hatékony kezelés ezen mellékhatás megelőzésére/kezelésére, ezért a szövődmény prevenciója, korai felismerése és a daganatellenes terápia időben történő módosítása különösen nagy jelentőségű. A daganatellenes kezelés következtében létrejött neuropathia diagnosztikájának egységesítésével, megelőzésével és kezelésével kapcsolatos klinikai vizsgálatok mellett a károsodás patomechanizmusának, genetikai hátterének feltárását célzó alapkutatások folytatása is szükséges. Munkánk során áttekintjük a daganatellenes kezelés indukálta neuropathia pathomechanizmusát, diagnosztikáját és javaslatot teszünk egy új, (a már meglevő kérdőívek elemeit felhasználó) egyszerű kérdőív használatára, mely hangvillavizsgálattal kiegészítve segíti a neuropathia diagnózisának gyors, betegágy melletti felállítását. Ezen túlmenően kitérünk a szövődmény megelőzésének és kezelésének új lehetőségeire és rámutatunk a jelenlegi kutatási irányokra. Ezek eredményeképpen a jövőben a kemoterápia indukálta neuropathiával szembeni (gyógyszeres és nem gyógyszeres) fegyvertárunk bővülése várható. Chemotherapy induced peripheral neuropathy is a dose-limiting side-effect of several chemotherapeutic treatments. However, nerve injury can emerge not only in patients receiving classic chemotherapeutic drugs, but also in patients on new type anti-tumor treatment, such as proteasome inhibitors, immunmodulants and molecularly targeted therapies. This side-effect leads to a diminished quality of life not only during treatment, but it can be a permanent problem afterwards as well and it may force the clinician to reduce or suspend the dose of the drug which in turn may deteriorate the patient’s chances to be cured. As nowadays we do not have any approved efficient drugs available for treatment or prevention, early diagnosis of this complication is pivotal which includes altering the antitumor therapy in time. Besides clinical studies aiming at the diagnosis, prevention and treatment of antitumor therapy induced neuropathy, it is also necessary to continue with basic research investigating the pathomechanism and the genetic background of...